Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02898 盛禾生物-B
SUNHO BIO-B
Listing Date2024/05/24
Listing Price13.500
 
Quote
  • 5.200 +0.190 (+3.792%)    Sink Below Listing Price
  • 15-min delayed, last update: 01/11/2024 15:09
Subscription Result
  • Subscription Rate
    10.08x
  • Guarantee One Lot Size
    15 lot
  • One Lot Success Rate
    7.82%
COMPANY PROFILE

Sunho Biologics, Inc. was founded in 2018, it is a clinical stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases.

--

The Group have three Core Products, IAH0968, IAP0971 and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (“ADCC”) enhanced monoclonal antibody (“mAb”), and it have initiated Phase II clinical trials for biliary tract carcinoma (“BTC”) and colorectal cancer (“CRC”). IAP0971 and IAE0972 are both immunocytokines and it have completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (“NSCLC”) and CRC.

--

As of May 6, 2024, the Group had nine pipeline products, in addition to its Core Products, three of which were in the clinical stage, also focusing on the treatment of cancer.

--

The Group’s core business model involves internally discovering, developing and commercializing immunocytokines and other immunotherapies that regulate immune microenvironment by directly modulating both the innate and adaptive immune systems to address the market needs in the fields of oncology and autoimmune diseases.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot200
GLOBAL OFFERING
No. of Offer Shares34.15M shares
No. of International Offer Shares30.74M shares
No. of HK Offer Shares3.42M shares
Offer Price$13.50
Stock Code2898
Sponsor(s)China International Capital Corporation Hong Kong Securities Limited
Underwriter(s)China International Capital Corporation Hong Kong Securities Limited, China Galaxy International Securities (Hong Kong) Co., Limited, CMB International Capital Limited, Zhongtai International Securities Limited, ABCI Securities Company Limited, ICBC International Securities Limited, Citrus Securities Limited, Tiger Brokers (HK) Global Limited, Futu Securities International (Hong Kong) Limited, Victory Securities Company Limited, Grand China Securities Limited
TIME TABLE
Application PeriodMay 16 (Thu) - noon, May 21 (Tue)
Price Determination Date--
Result Announcement DateOn or before May 23 (Thu)
Result Announcement DateOn or before May 23 (Thu)
Result Announcement DateOn or before May 24 (Fri)
Dealings in Shares commence onMay 24, 2024. (Fri)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$13.50
Capitalization2.12B
NAV / share ($)$2.25 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 13.50, the net proceeds raised would be HKD 391.60M, of which
28.2% : Used for ongoing and planned clinical trials of IAH0968 in China
35.8% : Used for ongoing and planned clinical trials of IAP0971 in China
36% : Used to fund ongoing and planned clinical trials of IAE0972 in China
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
:
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.